ReviewDiabetes, obesity & metabolism2025

iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China.

Miao YuPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.